trending Market Intelligence /marketintelligence/en/news-insights/trending/MOx8yTIc1jvB3fC8kRu2vw2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Sangamo transfers gene therapy SB-525 to co-developer Pfizer

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Sangamo transfers gene therapy SB-525 to co-developer Pfizer

Sangamo Therapeutics Inc. has transferred SB-525 to Pfizer Inc., its partner in developing the gene therapy for treating the bleeding disorder hemophilia A.

As per their agreement, Richmond, Calif.-based Sangamo handled the early- and mid-stage trials of the drug while Pfizer will take charge of the drug's late-stage trial, expected in 2020.

SB-525 is an investigational gene therapy for severe hemophilia A, a genetic bleeding disorder in which the blood does not clot normally due to the absence or low levels of factor VIII, a protein needed to form blood clots.

Sangamo received $25 million as a milestone payment from New York-based pharmaceutical giant Pfizer.

Sangamo is eligible for total milestone payments of up to $300 million for developing and commercializing SB-525 and tiered royalties from the low teens up to 20% of net yearly sales of SB-525. The company will also receive up to $175 million for additional Hemophilia A gene therapies it co-develops with Pfizer.

The U.S. Food and Drug Administration tagged Sangamo-Pfizer's SB-525 as a regenerative medicine advanced therapy in July and gave it orphan-drug and fast-track designations in 2017.

The gene therapy has also received an orphan medicinal product status from the European Medicines Agency.